ACE2 News and Research

RSS

N501Y mutation in SARS-CoV-2 Delta variant is key to breakthrough infections

A study in the Philadelphia area found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants evolve to become more contagious and resistant to COVID-19 vaccines. In addition, depending on the sublineage, SARS-CoV-2 variants such as the Delta variant led to a three-fold increased risk for vaccine breakthrough cases.

25 Oct 2021

Regulating blood insulin levels in obese, diabetic patients may help reduce COVID-19 risk

Keeping blood insulin levels within strict, healthy parameters is a daily goal for people with diabetes. But now, researchers from Japan have found that regulating blood insulin levels may even help lower the risk of getting COVID-19.

25 Oct 2021

Are non-human primates at risk of SARS-CoV-2 exposure through wastewater contact?

Researchers have been investigating the potential for SARS-CoV-2 to spread to NHP through wastewater.

25 Oct 2021

Molecular features of SARS-CoV-2 variant receptor binding

Researchers have been investigating the changes in receptor binding in these variants that increase the danger they pose.

25 Oct 2021

Study finds FDA-approved drug has potent antiviral activity against SARS-CoV-2 and variants of concern

A new study aimed to examine the antiviral potential of atovaquone against the original SARS-CoV-2 strain and other variants of concern.

25 Oct 2021

Blood pressure drug increases SARS-CoV-2 receptors in transmission and pathogenesis associated tissues

A new study aimed to determine whether ACE2 targeting drugs change the tissue levels of ACE2 in healthy mice.

25 Oct 2021

Study suggests seropositive individuals produce anti-SARS-CoV-2 antibodies with improved potency and breadth

Researchers isolated single cells among individuals with and without prior infection with the SARS-CoV-2 vaccinated with BNT162b2 mRNA vaccine and compared the nature of the neutralizing antibody response against the original Wuhan virus and the subsequent variants.

25 Oct 2021

Cancer patients have impaired antibody responses to COVID-19 mRNA vaccines

A new study posted to the medRxiv* preprint server studies the neutralizing antibody response in cancer patients diagnosed with chronic lymphocytic leukemia (CLL), lung cancer, breast cancer, and various non-Hodgkin’s lymphomas (NHL), post-reception of two doses of messenger RNA (mRNA) vaccines.

25 Oct 2021

Immune evasion by SARS-CoV-2 facilitated by a mutational hotspot in the NTD

Researchers discuss mutations in the NTD of the spike protein, which contains an antigenic “supersite” and is the target for nAbs.

24 Oct 2021

Mu and C.1.2 variant spike proteins partially resistant to neutralization by vaccine-elicited antibodies

A team of researchers measured the infectivity of SARS-CoV-2 variants C.1.2, Mu, and Delta+501S spike proteins and determined the susceptibility to neutralizing antibodies.

22 Oct 2021

Replication of SARS-CoV-2 variants in different cell and organ models

In this study, the replication of B.1.1.7 viruses was analyzed in different cell and organ models and dwarf hamsters.

22 Oct 2021

Development of a safe and effective COVID-19 nanoparticle vaccine

Researchers from ReVacc scientific have attempted to demonstrate the effectiveness of a new vaccine, REVC-128, two weeks post-administration.

22 Oct 2021

Hydrogel-based vaccine delivery system evokes antibody response against SARS-CoV-2

Researchers from Stanford University have been attempting to create a hydrogel-based vaccine delivery system that could improve the immune response's strength and duration.

22 Oct 2021

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.

22 Oct 2021